Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clare Sun

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Blood|December 17, 2025
A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 StudyAndy Itsara, Victoria M Rogness, Laura Samples, et al.
Blood Advances|May 23, 2023
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targetingMaissa Mhibik, Erika M Gaglione, David Eik, et al.
Haematologica|October 3, 2015
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinibAndrew H Lipsky, Mohammed Z H Farooqui, Xin Tian, et al.
Blood|September 5, 2015
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinibClare Sun, Xin Tian, Yuh Shan Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2015
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II StudyCarsten U Niemann, Sarah E M Herman, Irina Maric, et al.
Blood|March 24, 2020
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinibClare Sun, Pia Nierman, Ellen K Kendall, et al.
Nature Communications|December 21, 2017
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapyDan A Landau, Clare Sun, Daniel Rosebrock, et al.
Leukemia|January 12, 2017
Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral bloodThomas M Herndon, Shih-Shih Chen, Nakhle S Saba, et al.
Blood|November 14, 2022
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenograftsDeyi Zhang, Hailey M Harris, Jonathan Chen, et al.
Leukemia|April 28, 2021
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignanciesRichard R Furman, John C Byrd, Roger G Owen, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Blood|December 17, 2025
A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 StudyAndy Itsara, Victoria M Rogness, Laura Samples, et al.
Blood Advances|May 23, 2023
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targetingMaissa Mhibik, Erika M Gaglione, David Eik, et al.
Haematologica|October 3, 2015
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinibAndrew H Lipsky, Mohammed Z H Farooqui, Xin Tian, et al.
Blood|September 5, 2015
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinibClare Sun, Xin Tian, Yuh Shan Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2015
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II StudyCarsten U Niemann, Sarah E M Herman, Irina Maric, et al.
Blood|March 24, 2020
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinibClare Sun, Pia Nierman, Ellen K Kendall, et al.
Nature Communications|December 21, 2017
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapyDan A Landau, Clare Sun, Daniel Rosebrock, et al.
Leukemia|January 12, 2017
Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral bloodThomas M Herndon, Shih-Shih Chen, Nakhle S Saba, et al.
Blood|November 14, 2022
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenograftsDeyi Zhang, Hailey M Harris, Jonathan Chen, et al.
Leukemia|April 28, 2021
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignanciesRichard R Furman, John C Byrd, Roger G Owen, et al.
Pageof 6